Experiment 67296
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | SC |
| Organism | Viscum album (LORANTHACEAE) |
| Citation | LENARTZ,D: DOTT,U: MENZEL,J: SCHIERHOLZ,JM: BEUTH,J:. (2000). SURVIVAL OF GLIOMA PATIENTS AFTER COMPLEMENTARY TREATMENT WITH GALACTOSIDE-SPECIFIC LECTIN FROM MISTLETOE.. 20(3B) |
| Amount utilized | |
| Compound isolated | |
| Disease | 38 PATIENTS WITH PRIMARY BRAIN TUMORS WERE ENROLLED INTO THIS PROSPECTIVELY RANDOMIZED CLINICAL TRIAL. THE PATIENTS WERE RANDOMIZED INTO A TREATMENT GROUP AND A CONTROL GROUP AND COULD BE BE ADEQUATELY OBSERVED DURING A FOLLOW UP PERIOD OF 50 MONTHS AFTER TUMORDESTRUCTIVE TREATMENT. COMMERCIALLY AVAILABLE MISTLETOE EXTRACT(ML-1) WAS ADMINISTERED TO THE PATIENTS OF THE TREATMENT GROUP. EVALUATION OF RELAPSE FREE/OVERALL SURVIVAL WAS PERFORMED AFTER A 50 MONTHS FOLLOW UP TIME. NON-STRATIFIED ANALYSIS OF ALL THE PATIENTS REVEALED NON-RELEVANT PROLONGATION OF RELAPSE-FREE INTERVALS/OVERALL SURVIVAL TIME FOR THE TREATMENT GROUP. HOWEVER, ANALYSIS OF STRATIFIED STAGE III/IV GLIOMA PATIENTS DEMONSTRATED:1. A TENDENCY FOR A PROLONGATION OF RELAPSE-FREE SURVIVAL FOR PATIENTS OF THE TREATMENT GROUP VS. THE CONTROL GROUP. 2. A STATISTICALLY SIGNIFICANT PROLONGATION OF THE OVERALL SURVIVAL FOR THE TREATMENT GROUP AS COMPARED TO THE CONTROL GROUP. |
| Dose amount | 1.0 MG |
| Number | 2 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Extract | H2O EXT |
| Gender | GIVEN TO BOTH SEXES |